The Discounted Cash Flow (DCF) valuation of Y-mAbs Therapeutics, Inc (YMAB) is (37.46) USD. With the latest stock price at 4.30 USD, the upside of Y-mAbs Therapeutics, Inc based on DCF is -971.1%.
Based on the latest price of 4.30 USD and our DCF valuation, Y-mAbs Therapeutics, Inc (YMAB) is a sell. selling YMAB stocks now will result in a potential gain of 971.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.3% - 8.0% | 6.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (331.32) - (19.77) | (37.46) |
| Upside | -7805.2% - -559.7% | -971.1% |